Wahed Invest LLC Has $210,000 Stock Holdings in Bio-Techne Co. (NASDAQ:TECH)

Wahed Invest LLC grew its stake in Bio-Techne Co. (NASDAQ:TECH) by 12.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,980 shares of the biotechnology company’s stock after buying an additional 328 shares during the period. Wahed Invest LLC’s holdings in Bio-Techne were worth $210,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in TECH. Cerity Partners LLC boosted its position in shares of Bio-Techne by 831.4% during the 4th quarter. Cerity Partners LLC now owns 46,205 shares of the biotechnology company’s stock valued at $3,565,000 after purchasing an additional 41,244 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Bio-Techne by 19.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 734,105 shares of the biotechnology company’s stock valued at $56,646,000 after purchasing an additional 118,534 shares in the last quarter. Sei Investments Co. boosted its position in shares of Bio-Techne by 16.2% during the 4th quarter. Sei Investments Co. now owns 856,514 shares of the biotechnology company’s stock valued at $66,089,000 after purchasing an additional 119,295 shares in the last quarter. Hsbc Holdings PLC boosted its position in shares of Bio-Techne by 55.3% during the 4th quarter. Hsbc Holdings PLC now owns 261,370 shares of the biotechnology company’s stock valued at $20,166,000 after purchasing an additional 93,107 shares in the last quarter. Finally, TD Asset Management Inc boosted its position in shares of Bio-Techne by 9.7% during the 4th quarter. TD Asset Management Inc now owns 135,632 shares of the biotechnology company’s stock valued at $10,465,000 after purchasing an additional 11,947 shares in the last quarter. Institutional investors and hedge funds own 98.95% of the company’s stock.

Bio-Techne Stock Performance

Shares of TECH traded down $2.18 on Friday, reaching $80.17. 857,922 shares of the company’s stock traded hands, compared to its average volume of 1,067,713. The company has a current ratio of 4.08, a quick ratio of 2.88 and a debt-to-equity ratio of 0.19. The stock has a market cap of $12.63 billion, a PE ratio of 62.64, a PEG ratio of 8.51 and a beta of 1.29. The stock’s 50 day simple moving average is $76.26 and its two-hundred day simple moving average is $73.23. Bio-Techne Co. has a 52-week low of $51.79 and a 52-week high of $85.85.

Bio-Techne (NASDAQ:TECH) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. Bio-Techne had a return on equity of 13.60% and a net margin of 17.59%. The business had revenue of $303.43 million during the quarter, compared to the consensus estimate of $292.36 million. During the same period last year, the business posted $0.47 earnings per share. The business’s revenue for the quarter was up 3.2% on a year-over-year basis. On average, analysts forecast that Bio-Techne Co. will post 1.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Benchmark reiterated a “buy” rating and issued a $95.00 price target on shares of Bio-Techne in a report on Thursday, May 2nd. Robert W. Baird raised their target price on Bio-Techne from $73.00 to $81.00 and gave the company an “outperform” rating in a report on Thursday, May 2nd. Citigroup lowered Bio-Techne from a “buy” rating to a “neutral” rating and set a $85.00 target price on the stock. in a report on Wednesday, May 22nd. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on Bio-Techne from $85.00 to $82.00 and set a “buy” rating on the stock in a report on Thursday, April 18th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $81.00.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.